Jolicoeur E Marc, Ohman E Magnus, Temple Robert, Stockbridge Norman, Smith Sidney, Mark Daniel, Califf Robert M, Henry Timothy D, Chaitman Bernard R, Granger Christopher B
Duke University, Durham, NC, USA.
Am Heart J. 2008 Mar;155(3):435-44. doi: 10.1016/j.ahj.2007.12.005. Epub 2008 Jan 31.
The population of patients with advanced coronary artery disease (CAD) is growing as a result of the aging of the general population, the extensive use of revascularization, and the efficacy of therapies that have prolonged the survival of patients with severe atherosclerosis. Patients with symptomatic CAD survive to a point where little else can be done to relieve their angina. Despite an anticipated growth in the number of patients with this condition within the next few decades, advanced CAD receives relatively little attention by the medical and research communities. As a result, the scope of the disease is not well defined, its coverage in guidelines from professional associations is limited, and few new medical options are available. In response to this, a group of experts from different fields were brought together at a meeting held December 4 to 5, 2006. This document has been developed as a 2-part article. In the first part, the contemporary and emerging therapies for advanced CAD were reviewed. The present part reviews the current status of understanding of advanced CAD, the limits of contemporary therapies, and the difficulties in and barriers to the development of new treatments.
由于总体人口老龄化、血运重建的广泛应用以及延长严重动脉粥样硬化患者生存期的治疗方法的有效性，晚期冠状动脉疾病（CAD）患者的数量正在增加。有症状的CAD患者存活到几乎没有其他办法缓解其心绞痛的程度。尽管预计在未来几十年内患有这种疾病的患者数量会增加，但晚期CAD在医学和研究界受到的关注相对较少。因此，该疾病的范围没有得到很好的界定，专业协会指南中的涵盖范围有限，并且几乎没有新的医学选择。对此，来自不同领域的一组专家于2006年12月4日至5日举行的一次会议上齐聚一堂。本文档已编写为一篇分两部分的文章。第一部分回顾了晚期CAD的当代和新兴疗法。本部分回顾了对晚期CAD的当前理解状况、当代疗法的局限性以及新治疗方法开发中的困难和障碍。
